Hyperthermic intraperitoneal chemotherapy combined with systemic chemotherapy for gastric cancer peritoneal carcinomatosis

A protocol for systematic review and meta-analysis of randomized controlled trials

Yidan Lu, MD^{a,b}, Zheng Jin, MD^{c}, Song Zheng, PhD^{a,b,c,d},*, Yurong Bai, MD^{b,d}, Yangcheng Sun, MD^{b,d}

Abstract

Background: The prognosis of gastric cancer peritoneal carcinomatosis (GCPC) remains poor despite recent advances in systemic chemotherapy (SC) with an average survival less than 6 months. Current evidence supporting the utility of hyperthermic intraperitoneal chemotherapy (HIPEC) combined with SC for GCPC is limited. We plan to provide a systematic review and meta-analysis of randomized controlled trials to evaluate the comparative effects and safety of HIPEC combined with SC in the management of GCPC.

Methods: Randomized controlled trials evaluating HIPEC combined with SC versus SC as first-line treatment for GCPC will be searched in MEDLINE, EMBASE, Web of Science, the Cochrane Library, ClinicalTrials.gov, and Google Scholar, from database inception to April 30, 2020. Data on study design, participant characteristics, intervention details, and outcomes will be extracted. Primary outcomes to be assessed are: median progression-free survival; secondary outcomes are: median survival time, 1-year survival rate, 2-year survival rate, objective response rate, and adverse events. Meta-analysis will be performed using RevMan V.5.3 statistical software. Data will be combined with a random effect model. Study quality will be assessed using the Cochrane Risk of Bias Tool. Heterogeneity will be assessed, and if necessary, a subgroup analysis will be performed to explore the source of heterogeneity.

Results: The results will provide useful information about the effectiveness and safety of HIPEC combined with systemic chemotherapy regimens in patients with gastric cancer peritoneal carcinomatosis.

Conclusion: The findings of the study will be disseminated through peer-reviewed journal.

The registration number: INPLASY202050006.

DOI number: 10.37766/inplasy2020.5.0006.

YL and ZJ contributed equally to this work.

This study will not use primary data, and therefore, formal ethical approval is not required. The findings will be disseminated through peer-reviewed journals and committee conferences.

Ethics approval will not be required because all analyses in the present study will be performed based on data from published studies.

Patient consent for publication is not required.

Provenance and peer review is not commissioned; externally peer-reviewed.

This work was funded by the National Natural Science Foundation of China (81372660), Key Medical Science Research Fund of Hangzhou (2011ZD001), Medical Science Research Fund of Zhejiang Province, China (2013KYA157), Traditional Chinese Medicine Science and Technology Project of Zhejiang Province (2013ZA104), Zhejiang Province Public Welfare Technology Application Research Project (2011C33026), Hangzhou Science and Technology Bureau (20140633B30), and Department of Oncology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine (Hangzhou Cancer Hospital), Hangzhou, Zhejiang 310006, China.

The authors report no conflicts of interest.

Data sharing not applicable to this article as no datasets were generated or analyzed during the current study.

*Correspondence: Song Zheng, Department of Medical Oncology, Key Laboratory of Clinical Cancer Pharmacology and Toxicology Research of Zhejiang Province, Affiliated Hangzhou First People’s Hospital, Zhejiang University School of Medicine, Hangzhou Cancer Hospital, Hangzhou, Zhejiang 310006, China (e-mail: tztree@126.com).

Copyright © 2020 the Author(s). Published by Wolters Kluwer Health, Inc.

How to cite this article: Lu Y, Jin Z, Zheng S, Bai Y, Sun Y. Hyperthermic intraperitoneal chemotherapy combined with systemic chemotherapy for gastric cancer peritoneal carcinomatosis: a protocol for systematic review and meta-analysis of randomized controlled trials. Medicine 2020;99:27(e20973).

Received: 23 May 2020 / Accepted: 29 May 2020

http://dx.doi.org/10.1097/MD.0000000000020973
1. Introduction

Gastric cancer is among the most frequently occurring malignancies worldwide, as the fourth/fifth most common malignancy and the second leading cause of cancer-related deaths, with only about 25% of patients surviving for 5 years.\(^1,2\) Most patients with gastric cancer are in advanced stages when diagnosed, and peritoneal carcinomatosis is the most frequent site of metastasis.\(^3,4\) Systemic chemotherapy (SC) could improve the survival of patients with gastric metastatic cancer for 7 to 10 months.\(^5\) However, for patients with gastric cancer peritoneal carcinomatosis (GCPC), SC had limited efficacy. Peritoneal barrier makes the effective intraperitoneal concentration hard to achieve and only a small fraction of the systemically administered drug is delivered to the peritoneum.\(^6\) The prognosis of GCPC remains poor despite recent advances in SC with an average survival less than 6 months.\(^7-10\)

In the 1980s, Koga et al\(^11-13\) and Fujimoto et al\(^14\) applied hyperthermic intraperitoneal chemotherapy (HIPEC) to the treatment of gastric cancer. HIPEC is a technique characterized by the infusion of high concentration chemotherapy drugs at high temperature. Some studies had demonstrated for patients with advanced gastric cancer without peritoneal metastasis, radical resection combined with HIPEC can prevent patients from peritoneal metastasis and prolong the survival.\(^15-18\) For peritoneal metastasis, as a local manifestation of gastric cancer, a systemic disease, the comprehensive treatment mode based on SC is still adopted. A meta-analysis demonstrated that HIPEC combined with cytoreduction surgery had a beneficial effect on response in patients with advanced gastric cancer and GCPC.\(^19\) Zhao et al demonstrated that HIPEC combined with basic care of SC could extend the survival period, improve the quality of life, benefit the patients with advanced gastric cancer.\(^20\) The GYMSSA Trial (NCT00941655)\(^21\) indicated that HIPEC compared with SC, maximal cytoreduction surgery can achieve prolonged survival in selected patients with GCPC. But the sample size was only 16.

However, the current evidence supporting the efficacy of HIPEC combined with SC as first-line treatment for GCPC is limited. Therefore, we will conduct a meta-analysis to make comprehensive evaluations and compare HIPEC + SC with SC in patients with GCPC.

2. Methods

According to the recommendations specified in the Cochrane Handbook for Intervention Reviews\(^22\) we will perform the review and report it following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses statement.\(^23\)

2.1. Criteria for considering studies for this review

Eligibility criteria are formed in terms of the patients, interventions, comparison and outcomes (PICO) structure described below. Randomized controlled trials (RCTs) will be included in this study according to the criteria:

2.2. Patients (P)

Patients who had been pathologically diagnosed as gastric adenocarcinoma/gastroesophageal junction adenocarcinoma with peritoneal metastasis will be included.

2.3. Interventions/comparison (I-C)

The comparison of interventions will be designed as HIPEC + SC versus SC. In the HIPEC + SC groups, there should be a specific description of HIPEC with description of the drugs, regimens and the thermotherapy techniques used, including but not limited to: "intraperitoneal paclitaxel combined hyperthermia," "intraperitoneal hyperthermic perfusion," "hyperthermic peritoneal perfusion," and so on; All the studies on single intraperitoneal chemotherapy or hyperthermia including "early postoperative intraperitoneal chemotherapy" and "normal intraperitoneal chemotherapy" will be excluded. In SC groups, the procedures described as "SC," "oral chemotherapy," or "intravenous chemotherapy" for GCPC will be included.

2.4. Type of outcomes (O)

The primary outcome will be median progression-free survival. The secondary outcomes will be median survival time, 1-year survival rate, 2-year survival rate objective response rate, and adverse events.

2.5. Study design

Only RCTs will be included. Exclusion criteria will be:

1. non-RCTs, single-arm, unreasonable control setting;
2. observational studies, case reports, reviews, editorials and letters to editor;
3. duplicate studies, in vitro studies or animal studies, and
(4) no full-text, no data on any of the primary or secondary outcomes.

Unpublished trials and abstracts will be included if the methodology and data are accessible.

2.6. Search methods for identification of studies

Two investigators (YL and YB) will independently search the following electronic health databases: Medline (by PubMed, from database inception to April 30, 2020), EMBASE (by Elsevier), and Controlled Clinical Trials of the Cochrane Collaboration (Cochrane Central Register of Controlled Trials). We have used the following MeSH search terms and their synonyms: “hyperthermic intraperitoneal chemotherapy,” “stomach,” “gastric cancer,” “carcinosis,” “peritoneal carcinomatosis,” “comparative study,” “randomized controlled trials,” “prospective study,” and “comparative study.” To further increase the robustness of the literature search, we will recursively search references of relevant primary or secondary studies to identify additional eligible studies. If any up-to-date evidence is published during the review period, we will evaluate the eligibility of each study and consider its addition to the analysis. Endnote software will be utilized to remove duplicates. We will use predetermined inclusion criteria to estimate the eligibility of retrieved articles by title and abstract. We will review and consider the full-text if this information is insufficient for qualification assessment.

2.7. Data collection and analysis

2.7.1. Selection of studies. The 2 investigators will evaluate the title and summary independently (YL and ZJ) and will select studies that conform to the criteria to review the full-text, and then subsequently assess the adequacy to the proposed PICO criteria. In case of disagreement, a consensus meeting will take place before the final decision. The study selection procedure is illustrated in a Preferred Reporting Items for Systematic Reviews and Meta-Analyses flow chart (Fig. 1).

2.7.2. Data extraction and management. All the records retrieved from the databases are processed through EndNote X9. All extracted data are. Two investigators (YB and YS) will extract relevant data independently from all studies and store in a Microsoft Excel spreadsheet. The data included study features,
among studies will be assessed by calculating the risk. In case of disagreement, a discussion between the reviewers on Parmaretal method.[25] Risk ratios will be calculated for each outcome evaluated:

(1) bias arising from the randomization process,
(2) bias due to deviations from intended interventions,
(3) bias due to missing outcome data,
(4) bias in the measurement of the outcome, and
(5) bias in the selection of the reported result, and attrition and reporting bias by evaluating incomplete and selective data reporting.

Each project is assigned a judgement of high, low, or unclear risk. In case of disagreement, a discussion between the reviewers will take place before the final classification.

2.8. Data synthesis

Review Manager (RevMan) (Version 5.3. Copenhagen: The Nordic Cochrane Centre, The Cochrane Collaboration, 2014) was used to perform all the statistical analyses. Hazard ratios will be calculated for survival data. If there is no direct data, we will make an effort to extract data from Kaplan–Meier curves based on Parmaretal method.[25] Risk ratios will be calculated for discrete variables. Assuming to the assumption of inherently various study scenarios (HIPEC patterns, systematic chemotherapy regimens), a random-effects model will be assumed. When sufficient studies (≥10) are included in the analysis of primary outcomes, we will construct funnel plots to evaluate publication bias. Otherwise, Egger test will be applied.[26] Heterogeneity among studies will be assessed by calculating the $I^2$ statistic, whereby $I^2 < 25\%$ indicates no heterogeneity, $25\% \leq I^2 < 50\%$ indicates mild heterogeneity, $50\% \leq I^2 < 75\%$ indicates moderate heterogeneity and $I^2 \geq 75\%$ indicates large heterogeneity. If substantial heterogeneity (<50\%) is observed, subgroup analysis using the following variables may be performed to explore the source of heterogeneity: chemotherapy regimens; gender; grade of cancer; anatomical position; combination mode of intraperitoneal chemotherapy and hyperthermia.

2.9. Patient and public involvement

Given that the data collected in this systematic review and meta-analysis originate from previously published studies, patients and the general public were not involved in the process of research issues or outcome metrics that we want to evaluate.

3. Discussion

Most patients with peritoneal carcinomatosis of digestive tract origin die within 6 months.[28] National Comprehensive Cancer Network guidelines recommend peritoneal cytology be managed with SC or with supportive care.[29] The poor success of SC is likely because of the peritoneal-plasma barrier.[30] Intraperitoneal chemotherapy enables intraperitoneal tumors to be exposed to high concentrations of drugs, without increasing the blood concentration to toxic levels.[31] And hyperthermia accelerates blood circulation, thereby improving local drug concentration in the tumor so that the heat and drugs can be more evenly distributed.[32] Patients who may benefit the most from HIPEC are those whose disease burden is limited to positive cytology and limited nodal involvement.[33] So based on SC, we attempt to answer the question for the treatment strategies of GCPC clinically. It would be the first meta-analysis evaluating the efficacy and safety of HIPEC combined with SC for GCPC.

There are also some possible limitations to our review. There may be some heterogeneity across studies as the study designs are heterogeneous. To explore the possible sources of heterogeneity, we will perform a subgroup analysis. Therefore, the effects of various HIPECs on prognosis will also be analyzed. We aim to provide evidence-based suggestions for the clinical use of HIPEC.

Author contributions

Song Zheng is the guarantor. Yidan Lu and Zheng Jin drafted the manuscript protocol. Yidan Lu designed the search strategy and provided statistical expertise. Zheng Jin, Yurong Bai, and Yangchen Sun contributed to the development of the selection criteria, article screening strategy, risk of bias assessment strategy, and data extraction criteria. All authors read, provided feedback and approved the final protocol.

Correction

The funding information for the Zhejiang Province Public Welfare Technology Application Research Project appeared incorrectly as 2016C03SA100727 and has been corrected to 2017C33220.

References

[1] Torre LA, Bray F, Siegel RL, et al. Global cancer statistics, 2012. CA Cancer J Clin 2015;65:87–108.
[2] Khazaei S, Rezaeean S, Soleymanzad M, et al. Global incidence and mortality rates of stomach cancer and the human development index: an ecological study. Asian Pac J Cancer Prev 2016;17:1701–4.
[3] Veldie CJ, Peeters KC. The gastric cancer treatment controversy. J Clin Oncol 2003;21:2234–6.
[4] Shiozaki H, Elimova E, Slack RS, et al. Prognosis of gastric adenocarcinoma patients with various burdens of peritoneal metastases. J Surg Oncol 2016;111:29–35.
[5] Boku N, Yamamoto S, Fukuda H, et al. Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study. Lancet Oncol 2009;10:1063–9.
[6] Glehen O, Mohamed F, Gilly FN. Peritoneal carcinomatosis from digestive tract cancer: new management by cytoreductive surgery and intraperitoneal chemohyperthermia. Lancet Oncol 2004;5:219–28.
[7] Kang YK, Kang WK, Shun DK, et al. Capecebtabine/cisplatin versus S-fluorouracil/cisplatin as first-line therapy in patients with advanced gastric cancer: a randomised phase III noninferiority trial. Ann Oncol 2009;20:666–73.
[8] Cunningham D, Starling N, Rao S, et al. Capecebtabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 2008;358:36–46.
[9] Koizumi W, Narahara H, Hara T, et al. S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 2008;9:215–21.
[10] Bang YJ, Van Cut, Feyereislova A, Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-
positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 2010;376:687–97.

[11] Koga S, Hamazoe R, Maeta M, et al. Treatment of implanted peritoneal cancer in rats by continuous hyperthermic peritoneal perfusion in combination with an anticancer drug. Cancer Res 1984;44:1840–2.

[12] Koga S. Prophylactic and therapeutic continuous hyperthermic peritoneal perfusion for peritoneal metastases of gastric cancer. Gan no Rinsho Jpn J Cancer Clin 1985;31(9 Suppl):1103–5.

[13] Koga S, Hamazoe R, Maeta M, et al. Prophylactic therapy for peritoneal recurrence of gastric cancer by continuous hyperthermic peritoneal perfusion with mitomycin C. Cancer 1988;61:232–7.

[14] Fujimoto S, Shrestha RD, Kokubun M, et al. Intraperitoneal hyperthermic perfusion combined with surgery effective for gastric cancer patients with peritoneal seeding. Ann Surg 1988;208:36–41.

[15] Golse N, Bakrin N, Passot G, et al. Irritative procedures combining cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for peritoneal recurrence: postoperative and long-term results. J Surg Oncol 2012;106:197–203.

[16] Roman RY, Ohorchak MA, Zubarev GP, et al. Hyperthermic intraperitoneal chemoperfusion in combined treatment of locally advanced and disseminated gastric cancer: results of a single-centre retrospective study. Int J Hyperthermia 2014;30:159–65.

[17] Rovello F, Caruso S, Neri A, et al. Treatment and prevention of peritoneal carcinomatosis from gastric cancer by cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: overview and rationale. Eur J Surg Oncol 2013;39:1309–16.

[18] Emel C, Yutaka Y, Bjorn B, et al. Intraperitoneal chemotherapy and its evolving role in management of gastric cancer with peritoneal metastases. Chin J Cancer Res 2014;26:1–3.

[19] Liu YW, Du Y, Chen BA. Effect of hyperthermic intraperitoneal chemotherapy for gastric cancer patients: a meta-analysis of the randomized controlled trials. J Int Med Res 2019;47:5926–36.

[20] Zhao C, Dai C, Chen X. Whole-body hyperthermia combined with hyperthermic intraperitoneal chemotherapy for the treatment of stage IV advanced gastric cancer. Int J Hypertherm 2012;28:735–41.

[21] Rudloff U, Langan RC, Mullinax JE, et al. Impact of maximal cytoreductive surgery plus regional heated intraperitoneal chemotherapy (HIPEC) on outcome of patients with peritoneal carcinomatosis of gastric origin: results of the GYMSA trial. J Surg Oncol 2014;110:275–84.

[22] Cumpston M, Li T, Page MJ, et al. Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev 2019;10:Ed000142.

[23] Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 2009;339:b2535.

[24] Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.

[25] Parmar MKB, Torri V, Stewart L. Extracting summary statistics to perform meta-analyses of the published literature for survival endpoints. Stat Med 2004;17:2813–34.

[26] Egger M. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629–34.

[27] Higgins JP, Thompson SG, Deeks JJ, et al. Measuring inconsistency in meta-analyses. BMJ 2003;327:557–60.

[28] Beaujard AC, Glehen O, Caillot JL, et al. Intraperitoneal chemotherapy for digestive tract cancer patients with peritoneal carcinomatosis. Cancer 2000;88:2512–9.

[29] Pak LM, Coit DG, Eaton AA, et al. Percutaneous peritoneal lavage for the rapid staging of gastric and pancreatic cancer. Ann Surg Oncol 2017;24:1174–9.

[30] Macrì A, Morabito F. The use of intraperitoneal chemotherapy for gastric malignancies. Expert Rev Anticancer Ther 2019;19:879–88.

[31] Ishigami H, Fujiwara Y, Fukushima R, et al. Phase III trial comparing intraperitoneal and intravenous paclitaxel plus S-1 versus cisplatin plus S-1 in patients with gastric cancer with peritoneal metastasis: PHOENIX-GC trial. J Clin Oncol 2018;36:1922–9.

[32] El-Kareh AW, Secomb TW. A theoretical model for intraperitoneal delivery of cisplatin and the effect of hyperthermia on drug penetration distance. Neoplasia (New York, NY) 2004;6:117–27.

[33] Desiderio J, Chao J, Melstrom L, et al. The 30-year experience—a meta-analysis of randomised and high-quality non-randomised studies of hyperthermic intraperitoneal chemotherapy in the treatment of gastric cancer. Eur J Cancer 2017;79:1–4.